2026 Q3 - tulosraportti
17 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 16 | ||
| 5 | ||
| 17 | ||
| 56 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 23.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 6.2. | ||
2025 Q3 - tulosraportti 24.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·27.10.Has anything been communicated about why Ångman sold shares?
I was a bit worried when he sold the majority of his holding. As journalists from daily financial media often tend to do, I emailed the question and got a reply, nice and appreciated from Lars! "Thank you for the question and your interest in MedCap. It is about me intending to close down my private limited company at the beginning of next year and therefore needing to terminate the company's endowment insurance this year where these shares were held. Selling as an insider, I think it is most appropriate to do in connection with the publication of a report so this was then the last chance. Regards, Lars
·23.10.Report today: - Good, stable quarter - Organic growth of 5% (13% incl. acquisitions) - Unfortunately some terminated acquisition processes (I think they require a lot before a deal can happen) - Still sounds like they have quite a few active dialogues regarding acquisitions - There are some units that are struggling a bit, but they are working on improvement - XGX: 3 out of 20 drugs that were in the pipeline are now launched - XGX: Existing drugs also seem to have been launched in new geographies - So one should now be able to expect continuous improvement from Specialist Pharmaceuticals - Adjustment of contingent consideration for XGX, 36.4 MSEK. Perhaps due to taking longer to roll out new drugs - BR in very good shape. Hoping now for at least one acquisition in Q4 So, they are ticking along pretty well.
·6.8.Bullish on Medcap long-term, 2 good Qs in a row.The market is doing well! But good can always get better: - Hope Specialty Pharmaceuticals improve from Q3 onwards; gradual improvements likely according to CEO - Preferably 2 more acquisitions during 2026, which perhaps add 5-10% to the revenue- ·21.7.Report today! - Growth of 16% with good margins, really good! - One-off item: transaction cost -1.4 MSEK - One-off item: contingent consideration 6.4 MSEK (so XGX Pharma is probably a bit below expectations, it could also be that it takes longer than expected to get the pipeline out) - Business area Aids is doing great, Swedelift/Trident have improvement potential - Business area Medical Technology is doing really well, Multi-Ply slightly better in the quarter, but can do better - Business area Specialty Pharmaceuticals, Sounds like new products from the XGX Pharma pipeline will start reaching the market Q3/Q4 onwards; should mean a gradual improvement in revenue and margin, perhaps not until Q4...? - One acquisition in the quarter, but there is great scope for more acquisitions. Hope they find at least 2 more acquisitions during 2026 I think the market should trade up the stock today I have a forward-looking P/E of approx 27 in my forecast.
Agree about good report. Would have used Ebita to value as they write off a lot of intangible assets. Has approx 14x EV/Ebita for next year if they can get another acquisition. Cheap for one of the stock market's best acquirers, in my opinion. - ·29.6.Acquisition - finally!! - Not huge, will add about 3-4% to revenue - As usual, always a bit of risk with Danish acquisitions - Copilot says Biopsafe has a margin of 12-13 % - Gives a P/E of 18-19, so quite expensive. Still believe MedCap has done its homework and that this will turn out well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |
2026 Q3 - tulosraportti
17 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27.10.Has anything been communicated about why Ångman sold shares?I was a bit worried when he sold the majority of his holding. As journalists from daily financial media often tend to do, I emailed the question and got a reply, nice and appreciated from Lars! "Thank you for the question and your interest in MedCap. It is about me intending to close down my private limited company at the beginning of next year and therefore needing to terminate the company's endowment insurance this year where these shares were held. Selling as an insider, I think it is most appropriate to do in connection with the publication of a report so this was then the last chance. Regards, Lars
- ·23.10.Report today: - Good, stable quarter - Organic growth of 5% (13% incl. acquisitions) - Unfortunately some terminated acquisition processes (I think they require a lot before a deal can happen) - Still sounds like they have quite a few active dialogues regarding acquisitions - There are some units that are struggling a bit, but they are working on improvement - XGX: 3 out of 20 drugs that were in the pipeline are now launched - XGX: Existing drugs also seem to have been launched in new geographies - So one should now be able to expect continuous improvement from Specialist Pharmaceuticals - Adjustment of contingent consideration for XGX, 36.4 MSEK. Perhaps due to taking longer to roll out new drugs - BR in very good shape. Hoping now for at least one acquisition in Q4 So, they are ticking along pretty well.
- ·6.8.Bullish on Medcap long-term, 2 good Qs in a row.The market is doing well! But good can always get better: - Hope Specialty Pharmaceuticals improve from Q3 onwards; gradual improvements likely according to CEO - Preferably 2 more acquisitions during 2026, which perhaps add 5-10% to the revenue
- ·21.7.Report today! - Growth of 16% with good margins, really good! - One-off item: transaction cost -1.4 MSEK - One-off item: contingent consideration 6.4 MSEK (so XGX Pharma is probably a bit below expectations, it could also be that it takes longer than expected to get the pipeline out) - Business area Aids is doing great, Swedelift/Trident have improvement potential - Business area Medical Technology is doing really well, Multi-Ply slightly better in the quarter, but can do better - Business area Specialty Pharmaceuticals, Sounds like new products from the XGX Pharma pipeline will start reaching the market Q3/Q4 onwards; should mean a gradual improvement in revenue and margin, perhaps not until Q4...? - One acquisition in the quarter, but there is great scope for more acquisitions. Hope they find at least 2 more acquisitions during 2026 I think the market should trade up the stock today I have a forward-looking P/E of approx 27 in my forecast.Agree about good report. Would have used Ebita to value as they write off a lot of intangible assets. Has approx 14x EV/Ebita for next year if they can get another acquisition. Cheap for one of the stock market's best acquirers, in my opinion.
- ·29.6.Acquisition - finally!! - Not huge, will add about 3-4% to revenue - As usual, always a bit of risk with Danish acquisitions - Copilot says Biopsafe has a margin of 12-13 % - Gives a P/E of 18-19, so quite expensive. Still believe MedCap has done its homework and that this will turn out well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 16 | ||
| 5 | ||
| 17 | ||
| 56 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 23.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 6.2. | ||
2025 Q3 - tulosraportti 24.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |
2026 Q3 - tulosraportti
17 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 5.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 23.10. | ||
2026 Q2 - tulosraportti 21.7. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 6.2. | ||
2025 Q3 - tulosraportti 24.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·27.10.Has anything been communicated about why Ångman sold shares?I was a bit worried when he sold the majority of his holding. As journalists from daily financial media often tend to do, I emailed the question and got a reply, nice and appreciated from Lars! "Thank you for the question and your interest in MedCap. It is about me intending to close down my private limited company at the beginning of next year and therefore needing to terminate the company's endowment insurance this year where these shares were held. Selling as an insider, I think it is most appropriate to do in connection with the publication of a report so this was then the last chance. Regards, Lars
- ·23.10.Report today: - Good, stable quarter - Organic growth of 5% (13% incl. acquisitions) - Unfortunately some terminated acquisition processes (I think they require a lot before a deal can happen) - Still sounds like they have quite a few active dialogues regarding acquisitions - There are some units that are struggling a bit, but they are working on improvement - XGX: 3 out of 20 drugs that were in the pipeline are now launched - XGX: Existing drugs also seem to have been launched in new geographies - So one should now be able to expect continuous improvement from Specialist Pharmaceuticals - Adjustment of contingent consideration for XGX, 36.4 MSEK. Perhaps due to taking longer to roll out new drugs - BR in very good shape. Hoping now for at least one acquisition in Q4 So, they are ticking along pretty well.
- ·6.8.Bullish on Medcap long-term, 2 good Qs in a row.The market is doing well! But good can always get better: - Hope Specialty Pharmaceuticals improve from Q3 onwards; gradual improvements likely according to CEO - Preferably 2 more acquisitions during 2026, which perhaps add 5-10% to the revenue
- ·21.7.Report today! - Growth of 16% with good margins, really good! - One-off item: transaction cost -1.4 MSEK - One-off item: contingent consideration 6.4 MSEK (so XGX Pharma is probably a bit below expectations, it could also be that it takes longer than expected to get the pipeline out) - Business area Aids is doing great, Swedelift/Trident have improvement potential - Business area Medical Technology is doing really well, Multi-Ply slightly better in the quarter, but can do better - Business area Specialty Pharmaceuticals, Sounds like new products from the XGX Pharma pipeline will start reaching the market Q3/Q4 onwards; should mean a gradual improvement in revenue and margin, perhaps not until Q4...? - One acquisition in the quarter, but there is great scope for more acquisitions. Hope they find at least 2 more acquisitions during 2026 I think the market should trade up the stock today I have a forward-looking P/E of approx 27 in my forecast.Agree about good report. Would have used Ebita to value as they write off a lot of intangible assets. Has approx 14x EV/Ebita for next year if they can get another acquisition. Cheap for one of the stock market's best acquirers, in my opinion.
- ·29.6.Acquisition - finally!! - Not huge, will add about 3-4% to revenue - As usual, always a bit of risk with Danish acquisitions - Copilot says Biopsafe has a margin of 12-13 % - Gives a P/E of 18-19, so quite expensive. Still believe MedCap has done its homework and that this will turn out well
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 5 | ||
| 16 | ||
| 5 | ||
| 17 | ||
| 56 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 413 | 4 413 | 0 | 0 |